Erratum: Phase II Study of Taselisib in PIK3CA-Mutated Solid Tumors Other Than Breast and Squamous Lung Cancer: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol I (JCO Prec Oncol DOI: 10.1200/PO.21.00424)

Brian M. Slomovitz

doi:10.1200/PO.22.00116

Erratum: Phase II Study of Taselisib in PIK3CA-Mutated Solid Tumors Other Than Breast and Squamous Lung Cancer: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol I (JCO Prec Oncol DOI: 10.1200/PO.21.00424)

Research output: Contribution to journal › Comment/debate › peer-review

Abstract

The article by Krop et al entitled “Phase II Study of Taselisib in PIK3CA-Mutated Solid Tumors Other Than Breast and Squamous Lung Cancer: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol I” (JCO Prec Oncol 10.1200/PO.21. 00424) was published online February 9, 2022, with an error.

Original language	English (US)
Article number	e2200116
Journal	JCO Precision Oncology
Volume	6
DOIs	https://doi.org/10.1200/PO.22.00116
State	Published - 2022
Externally published	Yes

ASJC Scopus subject areas

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1200/PO.22.00116

Fingerprint

Dive into the research topics of 'Erratum: Phase II Study of Taselisib in PIK3CA-Mutated Solid Tumors Other Than Breast and Squamous Lung Cancer: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol I (JCO Prec Oncol DOI: 10.1200/PO.21.00424)'. Together they form a unique fingerprint.

Cite this

Erratum : Phase II Study of Taselisib in PIK3CA-Mutated Solid Tumors Other Than Breast and Squamous Lung Cancer: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol I (JCO Prec Oncol DOI: 10.1200/PO.21.00424). / Slomovitz, Brian M.

In: JCO Precision Oncology, Vol. 6, e2200116, 2022.

Research output: Contribution to journal › Comment/debate › peer-review

@article{f04bfa892bed48459d2689fa3cf5c89b,

title = "Erratum: Phase II Study of Taselisib in PIK3CA-Mutated Solid Tumors Other Than Breast and Squamous Lung Cancer: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol I (JCO Prec Oncol DOI: 10.1200/PO.21.00424)",

abstract = "The article by Krop et al entitled “Phase II Study of Taselisib in PIK3CA-Mutated Solid Tumors Other Than Breast and Squamous Lung Cancer: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol I” (JCO Prec Oncol 10.1200/PO.21. 00424) was published online February 9, 2022, with an error.",

author = "Slomovitz, {Brian M.}",

note = "Publisher Copyright: {\textcopyright} 2022 by American Society of Clinical Oncology",

year = "2022",

doi = "10.1200/PO.22.00116",

language = "English (US)",

volume = "6",

journal = "JCO Precision Oncology",

issn = "2473-4284",

publisher = "American Society of Clinical Oncology",

}

TY - JOUR

T1 - Erratum

T2 - Phase II Study of Taselisib in PIK3CA-Mutated Solid Tumors Other Than Breast and Squamous Lung Cancer: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol I (JCO Prec Oncol DOI: 10.1200/PO.21.00424)

AU - Slomovitz, Brian M.

PY - 2022

Y1 - 2022

N2 - The article by Krop et al entitled “Phase II Study of Taselisib in PIK3CA-Mutated Solid Tumors Other Than Breast and Squamous Lung Cancer: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol I” (JCO Prec Oncol 10.1200/PO.21. 00424) was published online February 9, 2022, with an error.

AB - The article by Krop et al entitled “Phase II Study of Taselisib in PIK3CA-Mutated Solid Tumors Other Than Breast and Squamous Lung Cancer: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol I” (JCO Prec Oncol 10.1200/PO.21. 00424) was published online February 9, 2022, with an error.

UR - http://www.scopus.com/inward/record.url?scp=85127886890&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85127886890&partnerID=8YFLogxK

U2 - 10.1200/PO.22.00116

DO - 10.1200/PO.22.00116

M3 - Comment/debate

AN - SCOPUS:85127886890

VL - 6

JO - JCO Precision Oncology

JF - JCO Precision Oncology

SN - 2473-4284

M1 - e2200116

ER -

Erratum: Phase II Study of Taselisib in PIK3CA-Mutated Solid Tumors Other Than Breast and Squamous Lung Cancer: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol I (JCO Prec Oncol DOI: 10.1200/PO.21.00424)

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this